Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

about

Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

P2860

Q39455425-76DF96BB-4A7D-4D5B-B9A9-84024196A5BD Q40138970-BF563307-1ED4-4347-B467-04D9C1411E6C

P2860

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Item

http://www.wikidata.org/entity/Q38346533

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Combining doxorubicin and lipo ...... MDA-MB-435 breast tumor model.

@en

type

Item

label

Combining doxorubicin and lipo ...... MDA-MB-435 breast tumor model.

@en

prefLabel

Combining doxorubicin and lipo ...... MDA-MB-435 breast tumor model.

@en

P1476

Combining doxorubicin and lipo ...... MDA-MB-435 breast tumor model.

@en

P2093

Dana Masin

http://www.w3.org/2001/XMLSchema#string

Dawn N Waterhouse

http://www.w3.org/2001/XMLSchema#string

Karen A Gelmon

http://www.w3.org/2001/XMLSchema#string

Marcel B Bally

http://www.w3.org/2001/XMLSchema#string

P2860

Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis.

Molecular mechanisms of action of antisense drugs.

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

HER2/neu antisense targeting of human breast carcinoma.

Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.

ErbB2 pathways in heart and neural diseases.

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models

Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells.

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.

P304

261-271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1533-869X.2003.01099.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14696623

http://www.w3.org/2001/XMLSchema#string

P921

MDA-MB-435

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

about

P2860

P2860

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921